Vitex agnus-castus (chaste-tree/berry) in the treatment of menopause-related complaints

Journal of Alternative and Complementary Medicine

Volumn 15, Issue 8, 2009, Pages 853-862

  Van Die, Margaret Diana ^a   Burger, Henry G ^b   Teede, Helena J ^c   Bone, Kerry M ^d,e  

^a RMIT UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MediHerb   (Australia)

^e UNIVERSITY OF NEW ENGLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGELICA SINENSIS EXTRACT; AVENA SATIVA EXTRACT; BORON; CIMICIFUGA RACEMOSA EXTRACT; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ELEUTHEROCOCCUS SENTICOSUS EXTRACT; EPIMEDIUM GRANDIFLORUM EXTRACT; EUPATORIUM PURPUREUM EXTRACT; GLYCYRRHIZA GLABRA EXTRACT; LIGUSTICUM CHUANXIONG EXTRACT; MEDICAGO SATIVA EXTRACT; MELATONIN; MITCHELLA REPENS EXTRACT; NIGELLA SATIVA EXTRACT; PEPPERMINT; PLANT EXTRACT; POLYGONATUM MULTIFLORUM EXTRACT; PUNICA GRANATUM EXTRACT; ROSMARINUS OFFICINALIS EXTRACT; RUBUS IDAEUS EXTRACT; SCHISANDRA CHINENSIS EXTRACT; TARAXACUM OFFICINALIS EXTRACT; UNCLASSIFIED DRUG; VALERIAN; VIBURNUM OPULUS EXTRACT; VITEX AGNUS CASTUS EXTRACT;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HERB; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; MOOD DISORDER; NIGHT SWEAT; NONHUMAN; PERIMENOPAUSAL PREMENSTRUAL SYNDROME; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VASOMOTOR DISORDER; VITEX AGNUS CASTUS;

FEMALE; FRUIT; HOT FLASHES; HUMANS; MENOPAUSE; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITEX;

EID: 70349366931     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2008.0447     Document Type: Review

References (126)

1. Mills S, Bone K. Principles and Practice of Phytotherapy. London: Churchill Livingstone, 2000.
2. Pizzorno J, Murray M. Textbook of Natural Medicine. New York: Churchill Livingstone, 2000.
3. Hawley R, Levick B, eds. Women in Antiquity: New Assessments. London, New York: Routledge, 1995.
4. Hobbs C. Vitex: The Women's Herb. 2nd ed. Santa Cruz, CA: Botanica Press, 1990.
5. Attelmann H, Bends K, Hellenkemper H, Warkalla H. Agnolyt- in the treatment of gynecological complaints [in German]. Z Prä klin Geriatr 1972;2:239-243.
6. Fugh-Berman A. Herbs, phytoestrogens, and other CAM therapies. In: Lobo R, ed. Treatment of the Postmenopausal Woman. Basic and Clinical Aspects. 3rd ed. Burlington, MA: Academic Press, 2007:683.
7. Bone K. A Clinical Guide to Blending Liquid Herbs. St. Louis: Churchill Livingstone, 2003.
8. Mills S. The Dictionary of Modern Herbalism. Wellingborough, UK: Thorsons, 1985.
9. Newall C, Anderson L, Phillipson J. Herbal Medicines: A Guide for Health-care Professionals. London: The Pharmaceutical Press, 1996.
10. Christie S, Walker AF. Vitex agnus-castus L.: (1) A Review of Its Traditional and Modern Therapeutic use; (2) Current Use from a Survey of Practitioners. Eur J Herbal Med 1997;3:29-45.
11. Rotem C, Kaplan B. Phyto-female complex for the relief of hot flushes, night sweats and quality of sleep: Randomized, controlled, double-blind pilot study. Gynecol Endocrinol 2007;23:117-122.
12. Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: A randomized trial. Ann Intern Med 2006;145:869-879.
13. van Die MD, Burger HG, Bone KM, et al. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms. Menopause 2009;16:156-163.
14. Smolinski D, Wollner D, Orlowski J, et al. A pilot study to examine a combination botanical for the treatment of menopausal symptoms. J Altern Complement Med 2005; 11:483-489.
15. Wuttke W, Gorkow C, Jarry H. Dopaminergic compounds in Vitex agnus-castus. In: Leow D, Rietbrock, N, ed. Herbal Medicine in Research and Clinical Application [in German]. Darmstadt, Germany: Steinkopff (Verlag), 1995:81-91.
16. Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus): Pharmacology and clinical indications. Phytomedicine 2003;10:348-357.
17. Wuttke W. The use of chasteberry (Vitex agnus castus) extract in gynecology. Gynakol Endokrinol 2008;6:82-86.
18. Meier B, Berger D, Hoberg E, et al. Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine 2000;7:373-381.
19. Webster DE, Lu J, Chen SN, et al. Activation of the muopiate receptor by Vitex agnus-castus methanol extracts: Implication for its use in PMS. J Ethnopharmacol 2006;106: 216-221.
20. Dericks-Tan JS, Schwinn P, Hildt C. Dose-dependent stimulation of melatonin secretion after administration of Agnus castus: Experimental and clinical endocrinology & diabetes 2003;111:44-46.
21. Chopin Lucks B. Vitex agnus castus essential oil and menopausal balance: A research update. Complement Ther Nurs Midwifery 2003;9:157-160.
22. World Health Organisation. Research on the Menopause in the 1990s. Report of a WHO Scientific Group. WHO Technical Report Series No. 866. Geneva: WHO Library Cataloguing in Publication Data, 1996.
23. Lucks BC, Sørensen J, Veal L. Vitex agnus-castus essential oil and menopausal balance: A self-care survey. Complement Ther Nurs Midwifery 2002;8:148-154.
24. Mitchell E, Woods NF, Mariella A. Three stages of the menopausal transition from the Seattle Midlife Women's Health Study: Toward a more precise definition. Menopause 2000;7:334-349.
25. Burger H. The endocrinology of the menopause. J Steroid Biochem Molecular Biol 1999;69:31-35.
26. Burger H. The relationship between the endocrine characteristics and the regularity of menstrual cycles in the approach to menopause. Menopause 2005;12:276-1274
27. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495-1501.
28. Dennerstein L, Smith AM, Morse C, et al. Menopausal symptoms in Australian women. Med J Aust 1993;159:232-236.
29. Van Look PF, Lothian H, Hunter WM, et al. Hypothalamicpituitary- ovarian function in perimenopausal women. Clin Endocrinol (Oxf ) 1977;7:13-31.
30. Teede H, Buger H. The menopausal transition. In: Studd JW, ed. The Management of the Menopause. Annual Review. New York: Elsevier, 1998:1-18.
31. Guthrie JR, Dennerstein L, Taffe JR, et al. Hot flushes during the menopause transition: A longitudinal study in Australian-born women. Menopause 2005;12:460-467.
32. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-358.
33. Nilsson K, Heimer G. Endogenous estrogen levels in postmenopausal women with severe urogenital atrophy. Gynecol Obstet Invest 1992;34:234-236.
34. Burger H, Dudley E, Robertson D, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Hormone Res 2002;57:257-275.
35. Fraser IS, Baird DT. Blood production and ovarian secretion rates of estradiol-17 beta and estrone in women with dysfunctional uterine bleeding. J Clin Endocrinol Metab 1974;39:564-570.
36. Bungay GT, Vessey MP, McPherson CK. Study of symptoms in middle life with special reference to the menopause. Br Med J 1980;281:181-183.
37. Freeman EW, Sammel MD, Liu L, et al. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70.
38. Robinson GE. Psychotic and mood disorders associated with the perimenopausal period: Epidemiology, aetiology and management. CNS Drugs 2001;15:175-184.
39. Bromberger JT, Meyer PM, Kravitz HM, et al. Psychologic distress and natural menopause: A multiethnic community study. Am J Public Health 2001;91:1435-1442.
40. Hassan I, Ismail KM, O'Brien S. PMS in the perimenopause. J Br Menopause Soc 2004;10:151-156.
41. Erlik Y, Tataryn IV, Meldrum DR, et al. Association of waking episodes with menopausal hot flushes. JAMA 1981;245:1741-1744.
42. Shaver J, Giblin E, Lentz M, Lee K. Sleep patterns and stability in perimenopausal women. Sleep 1988;11:556-561.
43. Gonen R, Sharf M, Lavie P. The association between midsleep waking episodes and hot flashes in post-menopausal women. J Psychosom Obstet Gynecol 1986;5:113-117.
44. Freedman RR, Roehrs TA. Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance. Menopause 2006;13:576-583.
45. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: An hypothesis of flush mechanism. Clin Endocrinol (Oxf ) 1985;22:293-312.
46. Habib KE, Gold PW, Chrousos GP. Neuroendocrinology of stress. Endocrinol Metab Clin North Am 2001;30:695-728; vii-viii.
47. Finkelstein JW, Roffwarg HP, Boyar RM, et al. Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab 1972;35:665-670.
48. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 1998;21:553-566.
49. Joffe H, Hall JE, Soares CN, et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392-398.
50. Landgren BM, Collins A, Csemiczky G, et al. Menopause transition: Annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause. J Clin Endocrinol Metab 2004;89:2763-2769.
51. Burger H, Teede H. Endocrine changes during the perimenopause. In: Lobo R, ed. Treatment of the Postmenopausal Woman. Basic and Clinical Aspects. 3rd ed. Burlington, MA: Academic Press, 2007:67-76.
52. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: Evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987;65:1231-1237.
53. Metcalf MG, Donald RA, Livesey JH. Pituitary-ovarian function in normal women during the menopausal transition. Clin Endocrinol (Oxf ) 1981;14:245-255.
54. Robertson DM, Burger HG. Reproductive hormones: Ageing and the perimenopause. Acta Obstet Gynecol Scand 2002;81:612-616.
55. Lenton EA, Sexton L, Lee S, Cooke ID. Progressive changes in LH and FSH and LH: FSH ratio in women throughout reproductive life. Maturitas 1988;10:35-43.
56. Santoro N, Chervenak JL. The menopause transition. Endocrinol Metab Clin North Am 2004;33:627-636.
57. Burger HG. Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition: An analysis of FSH, oestradiol and inhibin. Eur J Endocrinol 1994;130:38-42.
58. Rannevik G, Carlstrom K, Jeppsson S, et al. A prospective long-term study in women from pre-menopause to postmenopause: Changing profiles of gonadotrophins, oestrogens and androgens. Maturitas 1986;8:297-307.
59. Longcope C, Franz C, Morello C, et al. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas 1986;8:189-196.
60. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84:4025-4030.
61. Prior JC. Perimenopause: The complex endocrinology of the menopausal transition. Endocr Rev 1998;19:397-428.
62. Miro F, Parker SW, Aspinall LJ, et al. Origins and consequences of the elongation of the human menstrual cycle during the menopausal transition: The FREEDOM Study. J Clin Endocrinol Metab 2004;89:4910-4915.
63. Weiss G, Skurnick JH, Goldsmith LT, et al. Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA 2004;292:2991-2996.
64. Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet 2008;371:1200-1210.
65. Genazzani AR, Salvestroni C, Spinetti A, et al. Estrogens and neurotransmitters. In: Studd JWW, ed. The Management of the Menopause: Annual Review 1998. Carnforth, Lancs, UK: The Parthenon Publishing Group Limited, 1998: 169-175.
66. Sherwin BB. Hormones, mood, and cognitive functioning in postmenopausal women. Obstet Gynecol 1996;87(2 Suppl): 20S-26S.
67. Maggi A, Perez J. Role of female gonadal hormones in the CNS: Clinical and experimental aspects. Life Sci 1985;37: 893-906.
68. Da Sliva I, Naftolin F. Clinical effects of sex steroids on the brain. In: Lobo R, ed. Treatment of the Postmenopausal Woman. Basic and Clinical Aspects. 3rd ed. Burlington, MA: Academic Press, 2007:199-215.
69. Nair NP, Hariharasubramanian N, Pilapil C, et al. Plasma melatonin: An index of brain aging in humans? Biol Psychiatry 1986;21:141-150.
70. Haimov I, Laudon M, Zisapel N, et al. Sleep disorders and melatonin rhythms in elderly people. BMJ 1994;309:167.
71. Vakkuri O, Kivela A, Leppaluoto J, et al. Decrease in melatonin precedes follicle-stimulating hormone increase during perimenopause. Eur J Endocrinol 1996;135:188-192.
72. Zimmerman R, Olcese J. Melatonin. In: Lobo R, ed. Treatment of the Postmenopausal Woman. Burlington, MA: Academic Press, 2007.
73. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001;13:453-464.
74. Bruck K, Zeisberger E. Adaptive changes in thermoregulation and their neuropharmacological basis. Pharmacol Ther 1987;35:163-215.
75. Biegon A, Reches A, Snyder L, McEwen BS. Serotonergic and noradrenergic receptors in the rat brain: Modulation by chronic exposure to ovarian hormones. Life Sci 1983;32: 2015-2021.
76. Tuchman E. Exploring the prevalence of menopause symptoms in midlife women in methadone maintenance treatment. Soc Work Health Care 2007;45:43-62.
77. Simpkins JW, Katovich MJ, Song IC. Similarities between morphine withdrawal in the rat and the menopausal hot flush. Life Sci 1983;32:1957-1966.
78. Barros RC, Branco LG, Carnio EC. Evidence for thermoregulation by dopamine D1 and D2 receptors in the anteroventral preoptic region during normoxia and hypoxia. Brain Res 2004;1030:165-171.
79. Cagnacci A, Melis GB, Soldani R, et al. Regulation of body temperature in postmenopausal women: Interactions between bromocriptine and the endogenous opioid system. Life Sci 1989;44:1395-1402.
80. Zichella L, Falaschi P, Fioretti P, et al. Effects of different dopamine agonists and antagonists on post-menopausal hot flushes. Maturitas 1986;8:229-237.
81. Blum I, Vered Y, Lifshitz A, et al. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women. Isr J Med Sci 1996;32: 1158-1162.
82. Gonzales GF, Carrillo C. Blood serotonin levels in postmenopausal women: Effects of age and serum oestradiol levels. Maturitas 1993;17:23-29.
83. Fink G, Sumner BE. Oestrogen and mental state. Nature 1996;383:306.
84. Dennerstein L, Lehert P, Guthrie JR, Burger HG. Modeling women's health during the menopausal transition: A longitudinal analysis. Menopause 2007;14:53-62.
85. Ballinger CB, Browning MC, Smith AH. Hormone profiles and psychological symptoms in peri-menopausal women. Maturitas 1987;9:235-251.
86. Chakravarti S, Collins WP, Newton JR, et al. Endocrine changes and symptomatology after oophorectomy in premenopausal women. Br J Obstet Gynaecol 1977;84:769-775.
87. Soares CN, Cohen LS. The perimenopause, depressive disorders, and hormonal variability. Sao Paulo Med J 2001; 119:78-83.
88. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375-382.
89. Avis NE, Kaufert PA, Lock M, et al. The evolution of menopausal symptoms. Baillieres Clin Endocrinol Metab 1993;7:17-32.
90. Barden N, Merand Y, Rouleau D, et al. Changes in the betaendorphin content of discrete hypothalamic nuclei during the estrous cycle of the rat. Brain Res 1981;204:441-445. (Pubitemid 11205716)
91. Genazzani AR, Petraglia F, Mercuri N, et al. Effect of steroid hormones and antihormones on hypothalamic betaendorphin concentrations in intact and castrated female rats. J Endocrinol Invest 1990;13:91-96.
92. Wise PM, Rance N, Barraclough CA. Effects of estradiol and progesterone on catecholamine turnover rates in discrete hypothalamic regions in ovariectomized rats. Endocrinology 1981;108:2186-2193. (Pubitemid 11048164)
93. Jacobs PA, Hyland ME. An evaluation of the benefits of taking hormone replacement therapy with other prescription drugs. Maturitas 2003;46:273-281.
94. Paoletti AM, Floris S, Mannias M, et al. Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. J Clin Endocrinol Metab 2001;86:608-612.
95. Parry BL, Newton RP. Chronobiological basis of femalespecific mood disorders. Neuropsychopharmacology 2001; 25(S5):S102-S108.
96. Khan SA, Pace JE, Cox ML, et al. Climacteric symptoms in healthy middle-aged women. Br J Clin Pract 1994;48:240-242.
97. Schmidt PJ, Nieman LK, Grover GN, et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. NEJM 1991;324:1174-1179.
98. Winer SA, Rapkin AJ. Premenstrual disorders: Prevalence, etiology and impact. J Reprod Med 2006;51(4 suppl):339-347.
99. Richards M, Rubinow DR, Daly RC, Schmidt PJ. Premenstrual symptoms and perimenopausal depression. Am J Psychiatry 2006;163:133-137.
100. Hale G, Hughes C, Burger H, et al. Atypical oestradiol secretion and ovulation patterns caused by Luteal Out- Of-Phase ("LOOP") events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause 2009;16:50-59.
101. Jarry H, Spengler B, Porzel A, et al. Evidence for estrogen receptor beta-selective activity of Vitex agnus-castus and isolated flavones. Planta Med 2003;69:945-947.
102. Yen SSC, Jaffe RB. Prolactin in human reproduction. In: Yen SSC, Jaffe RB, Barbieri RL, ed. Reproductive Endocrinology. 4th ed. Philadelphia: WB Saunders, 1999: 276-277.
103. Halbreich U, Ben-David M, Assael M, Bornstein R. Serumprolactin in women with premenstrual syndrome. Lancet 1976;2:654-656.
104. Muhlenstedt D, Bohnet HG, Hanker JP, Schneider HP. Short luteal phase and prolactin. Int J Fertil 1978;23:213-218.
105. Dietrich M, Hinnery B, Link M, et al. Latent hyperprolactinaemia as a cause of mastodynia and luteal function impairment. Vth International Congress Prolactin, 1988.
106. Giannini AJ, Martin DM, Turner CE. Beta-endorphin decline in late luteal phase dysphoric disorder. Int J Psychiatry Med 1990;20:279-284.
107. Chuong CJ, Hsi BP, Gibbons WE. Periovulatory betaendorphin levels in premenstrual syndrome. Obstet Gynecol 1994;83(5 Pt 1):755-760.
108. Facchinetti F, Moglia A, Bonuccelli U, et al. Pattern of plasma opioids in menstrually-related migraine and epilepsy. Funct Neurol 1986;1:415-419.
109. Facchinetti F, Martignoni E, Petraglia F, et al. Premenstrual fall of plasma beta-endorphin in patients with premenstrual syndrome. Fertil Steril 1987;47:570-573. (Pubitemid 17065617)
110. Diaz BL, Llaneza PC. Endocrine regulation of the course of menopause by oral melatonin: First case report. Menopause 2008;15:388-392.
111. Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a doubleblind placebo-controlled study: Effects on menopause symptoms and bone markers. Maturitas 2003;44(suppl 1): S67-S77.
112. Osmers R, Friede M, Liske E, et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005;105(5 Pt 1):1074-1083.
113. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of Cimicifuga racemosa on climacteric complaints: A randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol 2005;20:30-35.
114. Geller SE, Studee L. Contemporary alternatives to plant estrogens for menopause. Maturitas 2006;55(suppl 1):S3-S13.
115. US Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER). Guidance for industry: Labeling guidance for noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms- prescribing information for health care providers and patient labeling [revision 1]. Rockville, MD: Division of Drug Information, Center for Drug Evaluation and Research, CDER, 2004.
116. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978.
117. Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998;91:6-11.
118. Davis S, Briganti E, Chen RQ, et al. The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women. Med J Austr 2001;174:68-71.
119. Knight DC, Howes JB, Eden J. The effect of PromensilTM, an isoflavone extract, on menopausal symptoms. Climacteric 1999;2:79-84.
120. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: Prospective, randomised, placebo controlled study. BMJ 2001;322:134-137.
121. Lauritzen CH, Reuter HD, Repges R, et al. Treatment of premenstrual tension syndrome with Vitex agnus castus: Controlled, double-blind study versus pyridoxine. Phytomedicine 1997;4:183-189.
122. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2003;18:191-195.
123. Propping D, Bohnert KJ, Peeters M, et al. Vitex agnus castus. The treatment of gynaecological syndromes. [in German]. Therapeutikon 1991;5:581-585.
124. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med 2000;9:315-320.
125. Berger D, Schaffner W, Schrader E, et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet 2000;264:150-153.
126. Linde K, Mulrow CD. St John's wort for depression. Cochrane Database Sys Rev Abstracts 2000;2:CD000448.